Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) has announced it agreed to divest YUSIMRY (adalimumab-aqvh) to Hong Kong King-Friend Industrial Co. Ltd. (HKF) for up-front all-cash consideration of US$40 million. The closing of the transaction occurred on June 26, 2024. Meitheal Pharmaceuticals, Inc. (Meitheal), a wholly owned subsidiary of HKF, will continue to commercialize YUSIMRY in the US.
Latham represented Coherus in the transaction with a corporate deal team led by Bay Area partners Jekkie Kim, Ben Potter, and Josh Dubofsky, with associates Danny Nordstrom and Alex Bogdon. Advice was also provided on healthcare and life sciences matters by associates Fiona Gillan, Mizuna Sekine, and Patrick Chew; on tax matters by Bay Area partner Grace Lee, with associate Dennis Poehland; on data privacy matters by Bay Area partner Heather Deixler; and on securities matters by Bay Area partner Philip Stoup, with associate Tess Bloom.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
Lawyers and firms: get featured on Legal Desire
Share your deals, lateral moves, firm news and insights with 1M+ monthly readers: founders, law firm partners, general counsel and practising lawyers across the US, UK, EU and GCC.
Get featuredSubmit a press releaseThe advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
